HLB Life Science (KOSDAQ:A067630) - Share price, News & Analysis

A067630 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

A067630 Stock Overview

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally.

Risk Analysis

Earnings have declined by 52.1% per year over past 5 years

Highly volatile share price over the past 3 months

HLB Life Science Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HLB Life Science
Historical stock prices
Current Share Price	₩13,450.00
52 Week High	₩23,000.00
52 Week Low	₩9,310.00
Beta	0.21
1 Month Change	27.49%
3 Month Change	27.49%
1 Year Change	33.83%
3 Year Change	84.88%
5 Year Change	303.30%
Change since IPO	642.07%

Recent News & Updates

Apr 12

HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Feb 14

Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?

While HLB Life Science Co., Ltd. ( KOSDAQ:067630 ) shareholders are probably generally happy, the stock hasn't had...

Shareholder Returns

	A067630	KR Healthcare	KR Market
7D	35.2%	-0.8%	-3.3%
1Y	33.8%	-38.5%	-14.3%

Return vs Industry: A067630 exceeded the KR Healthcare industry which returned -38.5% over the past year.

Return vs Market: A067630 exceeded the KR Market which returned -14.3% over the past year.

Price Volatility

Is A067630's price volatile compared to industry and market?
A067630 volatility
A067630 Average Weekly Movement	10.7%
Healthcare Industry Average Movement	5.7%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.1%

Stable Share Price: A067630 is more volatile than 90% of KR stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: A067630's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
1998	41	Sung-Bo Sim	https://www.hlb-ls.com

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood.

HLB Life Science Fundamentals Summary

How do HLB Life Science's earnings and revenue compare to its market cap?
A067630 fundamental statistics
Market Cap	₩1.28t
Earnings (TTM)	-₩49.15b
Revenue (TTM)	₩53.49b

24.0x

P/S Ratio

-26.1x

P/E Ratio

Is A067630 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A067630 income statement (TTM)
Revenue	₩53.49b
Cost of Revenue	₩59.15b
Gross Profit	-₩5.66b
Other Expenses	₩43.49b
Earnings	-₩49.15b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-514.69
Gross Margin	-10.58%
Net Profit Margin	-91.88%
Debt/Equity Ratio	1.4%

How did A067630 perform over the long term?

See historical performance and comparison

Valuation

Is HLB Life Science undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

5.22x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A067630's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A067630's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A067630 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.

PE vs Market: A067630 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A067630's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A067630 is overvalued based on its PB Ratio (5.2x) compared to the KR Healthcare industry average (2.2x).

Future Growth

How is HLB Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

17.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HLB Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has HLB Life Science performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-52.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A067630 is currently unprofitable.

Growing Profit Margin: A067630 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A067630 is unprofitable, and losses have increased over the past 5 years at a rate of 52.1% per year.

Accelerating Growth: Unable to compare A067630's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A067630 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.4%).

Return on Equity

High ROE: A067630 has a negative Return on Equity (-19.99%), as it is currently unprofitable.

Financial Health

How is HLB Life Science's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A067630's short term assets (₩156.8B) exceed its short term liabilities (₩13.5B).

Long Term Liabilities: A067630's short term assets (₩156.8B) exceed its long term liabilities (₩10.7B).

Debt to Equity History and Analysis

Debt Level: A067630 has more cash than its total debt.

Reducing Debt: A067630's debt to equity ratio has reduced from 83.8% to 1.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A067630 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A067630 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 27.7% each year

Dividend

What is HLB Life Science current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A067630's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A067630's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A067630's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A067630's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A067630 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Sung-Bo Sim

no data

Tenure

Sung-Bo Sim serves as the Chief Executive Officer and President at HLB Life Science Co.,Ltd.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/13 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31